Clinical Trial

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Name: CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma — clinical trial record (NCT04661020)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2020-12-03; most recent amendment 2026-04-01.

Status change: Not Yet Recruiting → Recruiting 2023-12-12

Trial Details

NCT Number	NCT04661020
Lead Sponsor	Zhejiang University Collaborators: Yake Biotechnology Ltd.
Conditions	Large B-Cell Lymphoma (LBCL)
Enrollment	40 participants
Start Date	2020-12-03
Primary Completion	2026-12-20 (estimated)
Study Completion	2026-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-04-07